Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2004;110:3378-3383
doi: 10.1161/01.CIR.0000149840.46523.FC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frangioni, J. V.
Right arrow Articles by Hajjar, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frangioni, J. V.
Right arrow Articles by Hajjar, R. J.
Related Collections
Right arrow Cardiovascular imaging agents/Techniques

(Circulation. 2004;110:3378-3383.)
© 2004 American Heart Association, Inc.


Basic Science for Clinicians

In Vivo Tracking of Stem Cells for Clinical Trials in Cardiovascular Disease

John V. Frangioni, MD, PhD; Roger J. Hajjar, MD

From the Division of Hematology/Oncology, Department of Radiology, and Molecular Imaging Center, Beth Israel Deaconess Medical Center (J.V.F.); the Cardiology Laboratory of Integrative Physiology & Imaging, Cardiovascular Research Center, Massachusetts General Hospital (R.J.H.); and Harvard Medical School (J.V.F., R.J.H.), Boston, Mass.

Correspondence to John V. Frangioni, MD, PhD, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, SL-B05, Boston, MA 02215. E-mail jfrangio{at}bidmc.harvard.edu

Abstract

Various stem cells hold promise for the treatment of human cardiovascular disease. Regardless of stem cell origin, future clinical trials will require that the location and number of such cells be tracked in vivo, over long periods of time. The problem of tracking small numbers of cells in the body is a difficult one, and an optimal solution does not yet exist. We review the many contrast agents and detectors that have been proposed for stem cell tracking during clinical trials, define the characteristics of an ideal imaging technology, and suggest future directions for research.


Key Words: stem cells • imaging • trials • radiology




This article has been cited by other articles:


Home page
CirculationHome page
J. Terrovitis, M. Stuber, A. Youssef, S. Preece, M. Leppo, E. Kizana, M. Schar, G. Gerstenblith, R. G. Weiss, E. Marban, et al.
Magnetic Resonance Imaging Overestimates Ferumoxide-Labeled Stem Cell Survival After Transplantation in the Heart
Circulation, March 25, 2008; 117(12): 1555 - 1562.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
C.-P. Chen, M.-Y. Lee, J.-P. Huang, J. D. Aplin, Y.-H. Wu, C.-S. Hu, P.-C. Chen, H. Li, S.-M. Hwang, S.-H. Liu, et al.
Trafficking of Multipotent Mesenchymal Stromal Cells from Maternal Circulation Through the Placenta Involves Vascular Endothelial Growth Factor Receptor-1 and Integrins
Stem Cells, February 1, 2008; 26(2): 550 - 561.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
C. Valina, K. Pinkernell, Y.-H. Song, X. Bai, S. Sadat, R. J. Campeau, T. H. Le Jemtel, and E. Alt
Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction
Eur. Heart J., November 1, 2007; 28(21): 2667 - 2677.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. A. Jaffer, P. Libby, and R. Weissleder
Molecular Imaging of Cardiovascular Disease
Circulation, August 28, 2007; 116(9): 1052 - 1061.
[Full Text] [PDF]


Home page
Stem CellsHome page
A. B. Rosen, D. J. Kelly, A. J. T. Schuldt, J. Lu, I. A. Potapova, S. V. Doronin, K. J. Robichaud, R. B. Robinson, M. R. Rosen, P. R. Brink, et al.
Finding Fluorescent Needles in the Cardiac Haystack: Tracking Human Mesenchymal Stem Cells Labeled with Quantum Dots for Quantitative In Vivo Three-Dimensional Fluorescence Analysis
Stem Cells, August 1, 2007; 25(8): 2128 - 2138.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. L.M.A. Beeres, F. M. Bengel, J. Bartunek, D. E. Atsma, J. M. Hill, M. Vanderheyden, M. Penicka, M. J. Schalij, W. Wijns, and J. J. Bax
Role of Imaging in Cardiac Stem Cell Therapy
J. Am. Coll. Cardiol., March 20, 2007; 49(11): 1137 - 1148.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
T. Freyman, G. Polin, H. Osman, J. Crary, M. Lu, L. Cheng, M. Palasis, and R. L. Wilensky
A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction
Eur. Heart J., May 1, 2006; 27(9): 1114 - 1122.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. Cao, S. Lin, X. Xie, P. Ray, M. Patel, X. Zhang, M. Drukker, S. J. Dylla, A. J. Connolly, X. Chen, et al.
In Vivo Visualization of Embryonic Stem Cell Survival, Proliferation, and Migration After Cardiac Delivery
Circulation, February 21, 2006; 113(7): 1005 - 1014.
[Abstract] [Full Text] [PDF]